Biotheryx Entered into a Research Collaboration and License agreement with Incyte to Discover and Develop Targeted Protein Degraders
Shots:
- Biotheryx will receive a $7M technology access fee, and ~$6M in research & development funding, ~$347M in regulatory & commercial milestones along with royalties on global net product sales for the initial target
- The collaboration enables Biotheryx to identify & develop molecular glue degraders for multiple historically undruggable oncology targets using its PRODEGY platform for the treatment of cancers & inflammatory disease
- Incyte will lead the further development & commercialization of any molecular glue degraders discovered by the PRODEGY platform. Biotheryx’s pipeline of molecular glues incl. BTX-1188, a rationally designed, dual-targeting molecular glue degrader of GSPT1 & IKZF1/3 for AML & solid tumors
Ref: PR Newswire | Image: Biotheryx
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
